BioCentury
ARTICLE | Clinical News

FDA approves GSK's Krintafel to prevent malaria relapse

July 27, 2018 3:27 PM UTC

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Medicines for Malaria Venture (MMV) said FDA approved single-dose Krintafel tafenoquine to prevent relapse of Plasmodium vivax malaria in patients ages 16 and older who are receiving antimalarial therapy for acute P. vivax infection. Krintafel is the first new medicine approved for the indication in more than 60 years, according to the pharma...